New Bladder Cancer Treatment Shows 79% Survival at 2 Years

Nearly 80% of patients with advanced bladder cancer remained alive and cancer-free two years after receiving a new combination therapy, marking a breakthrough in treating a disease that has long had limited options.

The treatment pairs two powerful drugs: enfortumab vedotin, which delivers chemotherapy directly to cancer cells, and pembrolizumab, which unleashes the immune system to attack tumors. Together, they outperformed the standard chemotherapy in a major study involving over 800 patients across four continents.

The research, published in the New England Journal of Medicine, showed the combination eliminated all visible tumor signs in 56% of patients before surgery. That's nearly double the 33% success rate of traditional chemotherapy.

The journey to this breakthrough began at the University of Colorado Anschutz Medical Campus, where doctors treated one of the very first patients in the world with this combination. Dr. Thomas Flaig, who led the early research, watched the therapy progress from experimental to potentially lifesaving over several years of clinical trials.

For bladder cancer patients, the timing couldn't be better. The disease strikes nearly 85,000 Americans each year, and when it spreads beyond the bladder wall, survival rates drop to just 10% over five years.

The new treatment works like a precision strike force. The antibody drug conjugate acts as a guided missile, finding cancer cells by targeting a protein called nectin-4 on their surface and delivering chemotherapy payloads directly. Meanwhile, the immunotherapy drug disables the cancer's defense mechanism that normally shuts down immune responses.

Why This Inspires

A decade ago, bladder cancer research was stalling. Clinical trials couldn't find enough participants, and new drug approvals had ground nearly to a halt. Today, multiple new treatments are reaching patients, and researchers are actively developing even more options.

"It's a much more hopeful time for bladder cancer patients," Flaig says. The transformation from few options to multiple approved therapies represents years of persistence by researchers who refused to accept poor outcomes as inevitable.

The treatment does carry risks, including potential autoimmune reactions and nerve damage in fingers and toes. But for patients facing a cancer that invades the bladder's muscle layer, the dramatically improved survival rates offer hope that wasn't available just a few years ago.

The therapy has already become the preferred treatment for metastatic bladder cancer and now shows promise for the 25% of bladder cancer cases classified as muscle-invasive.

From treating the first patient to proving effectiveness in hundreds more, this Colorado-born therapy is rewriting what's possible for bladder cancer survival.